Serum indoleamine 2, 3-dioxygenase and tryptophan-2, 3-dioxygenase: potential biomarkers for the diagnosis of major depressive disorder.
3-Dioxygenase
Biomarkers
Indoleamine 2
Major depressive disorder
Tryptophan-2
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
received:
18
07
2023
accepted:
22
01
2024
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
29
1
2024
Statut:
aheadofprint
Résumé
The objective of this study was to observe the changes in the levels of indoleamine 2, 3-dioxygenase (IDO) and tryptophan-2, 3-dioxygenase (TDO) in patients with major depressive disorder (MDD) and investigate their potential role as novel biomarkers for diagnosing MDD. A total of 55 MDD patients and 55 healthy controls (HC) were enrolled in the study. The severity of MDD was assessed using the 24-item Hamilton Depression Rating Scale (HAMD-24) before and after treatment. The serum concentrations of IDO and TDO were measured at baseline and after treatment. The correlations between the serum levels of IDO and TDO and HAMD-24 scores were evaluated using Pearson's correlation test. Receiver operating characteristic (ROC) curve analysis was used to evaluate the area under the curve (AUC) of serum levels of IDO and TDO for discriminating MDD patients from HC. The serum IDO and TDO concentrations were significantly higher in patients with MDD at baseline than in healthy controls, and decreased significantly after 2 weeks or 1 month of treatment. The levels of IDO and TDO were significantly positively correlated with HAMD-24 scores. Furthermore, the AUC values for IDO and TDO were 0.999 and 0.966, respectively. The study suggests that serum IDO and TDO may serve as novel biomarkers for diagnosing MDD. These findings may lead to a better understanding of the pathogenesis of MDD and the development of new therapeutic targets.
Identifiants
pubmed: 38286858
doi: 10.1007/s00213-024-06542-8
pii: 10.1007/s00213-024-06542-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Hefei Health Applied Medicine
ID : hwk2020yb0015
Organisme : the Anhui Medical University
ID : 2020xkj064
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Al-Hakeim HK, Twayej AJ, Al-Dujaili AH, Maes M (2020) Plasma indoleamine-2,3-dioxygenase (IDO) is increased in drug-naï ve major depressed patients and treatment with sertraline and ketoprofen normalizes IDO in association with pro-inflammatory and immune- regulatory cytokines. CNS Neurol Disord Drug Targets 19:44–54
pubmed: 31894751
doi: 10.2174/1871527319666200102100307
Almeida FB, Pinna G, Barros HMT (2021) The role of HPA axis and allopregnanolone on the neurobiology of major depressive disorders and PTSD. Int J Mol Sci 22:5495
Anisman H, Hayley S (2012) Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal 5: pe45
Badawy AA (2013) Tryptophan: the key to boosting brain serotonin synthesis in depressive illness. J Psychopharmacol 27:878–893
pubmed: 23904410
doi: 10.1177/0269881113499209
Badawy AA (2017a) Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 10:1178646917691938
pubmed: 28469468
pmcid: 5398323
doi: 10.1177/1178646917691938
Badawy AA (2017b) Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology 112:248–263
pubmed: 26617070
doi: 10.1016/j.neuropharm.2015.11.015
Bano S, Gitay M, Ara I, Badawy A (2010) Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. Pak J Pharm Sci 23:266–272
pubmed: 20566438
Bilello JA (2016) Seeking an objective diagnosis of depression. Biomark Med 10:861–875
pubmed: 27415130
doi: 10.2217/bmm-2016-0076
Carabelli B, Delattre AM, Waltrick APF, Araújo G, Suchecki D, Machado RB, de Souza LER, Zanata SM, Zanoveli JM, Ferraz AC (2020) Fish-oil supplementation decreases Indoleamine-2,3-Dioxygenase expression and increases hippocampal serotonin levels in the LPS depression model. Behav Brain Res 390:112675
pubmed: 32407816
doi: 10.1016/j.bbr.2020.112675
Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, Turner RB (2012) Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A 109:5995–5999
pubmed: 22474371
pmcid: 3341031
doi: 10.1073/pnas.1118355109
Comai S, Bertazzo A, Brughera M, Crotti S (2020) Tryptophan in health and disease. Adv Clin Chem 95:165–218
pubmed: 32122523
doi: 10.1016/bs.acc.2019.08.005
Emmanuel T (2019) Remission of treatment-resistant depression with tardive akathisia with electroconvulsive therapy. BMJ Case Rep 12:e229714
Fatokun AA, Hunt NH, Ball HJ (2013) Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 45:1319–1329
pubmed: 24105077
doi: 10.1007/s00726-013-1602-1
Friedrich MJ (2017) Depression is the leading cause of disability around the world. JAMA 317:1517
pubmed: 28418491
Gao L, Gao T, Zeng T, Huang P, Wong NK, Dong Z, Li Y, Deng G, Wu Z, Lv Z (2021) Blockade of Indoleamine 2, 3-dioxygenase 1 ameliorates hippocampal neurogenesis and BOLD-fMRI signals in chronic stress precipitated depression. Aging (albany NY) 13:5875–5891
pubmed: 33591947
doi: 10.18632/aging.202511
Gao W, Xu Y, Liang J, Sun Y, Zhang Y, Shan F, Ge J, Xia Q (2022) Serum CC Chemokines as Potential Biomarkers for the Diagnosis of Major Depressive Disorder. Psychol Res Behav Manag 15:2971–2978
pubmed: 36310625
doi: 10.2147/PRBM.S384267
Gibney SM, Fagan EM, Waldron AM, O’Byrne J, Connor TJ, Harkin A (2014) Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int J Neuropsychopharmacol 17:917–928
pubmed: 24472498
doi: 10.1017/S1461145713001673
Höglund E, Øverli Ø, Winberg S (2019) Tryptophan Metabolic Pathways and Brain Serotonergic Activity: A Comparative Review. Front Endocrinol (lausanne) 10:158
pubmed: 31024440
doi: 10.3389/fendo.2019.00158
Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, Yu Y, Kou C, Xu X, Lu J, Wang Z, He S, Xu Y, He Y, Li T, Guo W, Tian H, Xu G, Xu X, Ma Y, Wang L, Wang L, Yan Y, Wang B, Xiao S, Zhou L, Li L, Tan L, Zhang T, Ma C, Li Q, Ding H, Geng H, Jia F, Shi J, Wang S, Zhang N, Du X, Du X, Wu Y (2019) Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry 6:211–224
pubmed: 30792114
doi: 10.1016/S2215-0366(18)30511-X
Hughes MM, Connor TJ, Harkin A (2016) Stress-Related Immune Markers in Depression: Implications for Treatment. Int J Neuropsychopharmacol 19:pyw001
pubmed: 26775294
pmcid: 4926799
doi: 10.1093/ijnp/pyw001
Jones BDM, Husain MI (2021) The Use of Sequential Pharmacotherapy for the Treatment of Acute Major Depression: a Scoping Review 22:1005–1014
Kanai M, Nakamura T, Funakoshi H (2009) Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci Res 64:111–117
pubmed: 19428689
doi: 10.1016/j.neures.2009.02.004
Kim YK, Jeon SW (2018) Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders. Curr Neuropharmacol 16:574–582
pubmed: 28901278
pmcid: 5997870
doi: 10.2174/1570159X15666170913110426
Koenig P, Nagl C, Neurauter G, Schennach H, Brandacher G, Fuchs D (2010) Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol 74:465–470
pubmed: 21084050
doi: 10.5414/CNP74465
Lai JY, Ho JX, Kow ASF, Liang G, Tham CL, Ho YC, Lee MT (2023) Interferon therapy and its association with depressive disorders - A review. Front Immunol 14:1048592
pubmed: 36911685
pmcid: 9992192
doi: 10.3389/fimmu.2023.1048592
Lanz TV, Williams SK, Stojic A, Iwantscheff S, Sonner JK, Grabitz C, Becker S, Böhler LI, Mohapatra SR, Sahm F, Küblbeck G, Nakamura T, Funakoshi H, Opitz CA, Wick W, Diem R, Platten M (2017) Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Sci Rep 7:41271
pubmed: 28117398
pmcid: 5259766
doi: 10.1038/srep41271
Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011) The new “5-HT” hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:702–721
pubmed: 21185346
doi: 10.1016/j.pnpbp.2010.12.017
Marttila S, Jylhävä J, Eklund C, Hervonen A, Jylhä M, Hurme M (2011) Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells. Immun Ageing 8:9
pubmed: 21989355
pmcid: 3198939
doi: 10.1186/1742-4933-8-9
Nobis A, Zalewski D, Waszkiewicz N (2020) Peripheral Markers of Depression. J Clin Med 9:3793
pubmed: 33255237
pmcid: 7760788
doi: 10.3390/jcm9123793
O’Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14:511–522
pubmed: 18195714
doi: 10.1038/sj.mp.4002148
Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, Wada M, Tarumi R, Plitman E, Moriguchi S, Miyazaki T, Uchida H, Graff-Guerrero A, Mimura M, Nakajima S (2018) Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev 90:16–25
pubmed: 29608993
doi: 10.1016/j.neubiorev.2018.03.023
Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF (2016) Major depressive disorder. Nat Rev Dis Primers 2:16065
pubmed: 27629598
doi: 10.1038/nrdp.2016.65
Pandarakalam JP (2018) Challenges of treatment-resistant depression. Psychiatr Danub 30:273–284
pubmed: 30267518
doi: 10.24869/psyd.2018.273
Papadopoulou ND, Mewies M, McLean KJ, Seward HE, Svistunenko DA, Munro AW, Raven EL (2005) Redox and spectroscopic properties of human indoleamine 2,3-dioxygenase and a His303Ala variant: implications for catalysis. Biochemistry 44:14318–14328
pubmed: 16245948
doi: 10.1021/bi0513958
Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA (2013) Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry 18:332–339
pubmed: 22158016
doi: 10.1038/mp.2011.166
Phillips C (2017) Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. Neural Plast 2017:7260130
pubmed: 28928987
doi: 10.1155/2017/7260130
Platten M, Nollen EAA, Röhrig UF (2019) Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov 18:379–401
pubmed: 30760888
doi: 10.1038/s41573-019-0016-5
Rehm J, Shield KD (2019) Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep 21:10
pubmed: 30729322
doi: 10.1007/s11920-019-0997-0
Savitz J (2020) The kynurenine pathway: a finger in every pie. Mol Psychiatry 25:131–147
pubmed: 30980044
doi: 10.1038/s41380-019-0414-4
Savonije K, Weaver DF (2023) The Role of Tryptophan Metabolism in Alzheimer’s Disease. Brain Sci 13:292
pubmed: 36831835
pmcid: 9954102
doi: 10.3390/brainsci13020292
Smith K (2014) Mental health: a world of depression. Nature 515:181
pubmed: 25391942
doi: 10.1038/515180a
Sorgdrager FJH, Doornbos B, Penninx B, de Jonge P, Kema IP (2017) The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls. J Affect Disord 222:32–39
pubmed: 28668713
doi: 10.1016/j.jad.2017.06.052
Strawbridge R, Young AH, Cleare AJ (2017) Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat 13:1245–1262
pubmed: 28546750
pmcid: 5436791
doi: 10.2147/NDT.S114542
van Baren N, Van den Eynde BJ (2015) Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol 6:34
pubmed: 25691885
pmcid: 4315104
van Buel EM, Meddens MJM, Arnoldussen EA, van den Heuvel ER, Bohlmeijer WC, den Boer JA, Muller Kobold A, Boonman-de Winter LJM, van Rumpt D, Timmers LFJ, Veerman MFA, Kamphuis JS, Gladkevich AV, Schoevers RA, Luiten PGM, Eisel ULM, Bosker FJ, Klein HC (2019) Major depressive disorder is associated with changes in a cluster of serum and urine biomarkers. J Psychosom Res 125:109796
pubmed: 31470255
doi: 10.1016/j.jpsychores.2019.109796
Wang X, Zhou X, Dai Q, Ji B, Feng Z (2017) The role of motivation in cognitive reappraisal for depressed patients. Front Hum Neurosci 11:516
pubmed: 29163097
pmcid: 5671608
doi: 10.3389/fnhum.2017.00516
Wohleb ES, Franklin T, Iwata M, Duman RS (2016) Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci 17:497–511
pubmed: 27277867
doi: 10.1038/nrn.2016.69
Wu X, Dai B, Yan F, Chen Y, Xu Y, Xia Q, Zhang X (2022) Serum Cortisol, Nesfatin-1, and IL-1β: Potential Diagnostic Biomarkers in Elderly Patients with Treatment-Resistant Depression. Clin Interv Aging 17:567–576
pubmed: 35480963
pmcid: 9038158
doi: 10.2147/CIA.S361459
Xu Y, Liang J, Gao W, Sun Y, Zhang Y, Shan F, Ge J, Xia Q (2022) Peripheral blood cytokines as potential diagnostic biomarkers of suicidal ideation in patients with first-episode drug-naïve major depressive disorder. Front Public Health 10:1021309
pubmed: 36420006
pmcid: 9678225
doi: 10.3389/fpubh.2022.1021309
Xu Y, Liang J, Sun Y, Zhang Y, Shan F, Ge J, Xia Q (2023) Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder. Int Immunopharmacol 118:110108
pubmed: 37004349
doi: 10.1016/j.intimp.2023.110108
Yu CP, Pan ZZ, Luo DY (2016) TDO as a therapeutic target in brain diseases. Metab Brain Dis 31:737–747
pubmed: 27072164
doi: 10.1007/s11011-016-9824-z